Dublin, Dec. 14, 2017 -- The "Flat-Rate Access to R&D Database & Reports from La Merie Publishing" newsletter has been added to Research and Markets' offering.
A one-year subscription to this product provides 24/7 online access to both services from the publisher with a 30% discount on the list prices for all license types. Internet access is the only prerequisite for this service.
Upon purchase of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.
1) Flat-Rate Subscription to La Merie Publishing Reports & News Services
A one-year subscription to this service provides access to:
- all existing reports on stock and listed online in the store;
- all new reports released by the publisher during the term of the subscription;
- 12 (monthly) issues of three different R&D and Business Tracking services;
- 50 (weekly) issues of R&D Pipeline News
Among the publisher's reports are:
- Competitor Analysis reports in tabular presentation format;
- Brief Reports; and Full Reports.
A full listing of existing reports can be found in the online store. Publishing activities include updates of existing reports as well as release of new reports.
Among the publisher's News & Information Services are:
- R&D and Business Tracker for TCR & CAR T-Cells and NK Cells;
- R&D and Business Tracker for Bispecific Antibodies;
- R&D and Business Tracker for Antibody-Drug Conjugates;
- R&D Pipeline News - Technology Edition;
- R&D Pipeline News - Therapeutic Area Edition.
For more information about this newsletter visit https://www.researchandmarkets.com/research/lptd5n/one_off_flatrate?w=12
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



